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Abstract
Background: The pathogenesis of osteonecrosis of the femoral head (ONFH) has been implicated in
hypofibrinolysis and blood supply interruption. Previous studies have demonstrated that decreased fibrinolytic
activity due to elevated plasminogen activator inhibitor-1 (PAI-1) levels correlates with ONFH pathogenesis. The
-675 4G/5G single nucleotide polymorphism (SNP rs1799889) in the PAI-1 gene promoter is associated with PAI-1
plasma level. We investigated whether rs1799889 and two other SNPs of the PAI-1 gene (rs2227631, -844 G/A in
the promoter; rs11178, +10700 C/T in the 3’UTR) are associated with increased ONFH risk.
Methods: Three SNPs in PAI-1 were genotyped in 206 ONFH patients and 251 control subjects, using direct
sequencing and a TaqMan
® 5’ allelic discrimination assay. We performed association analysis for genotyped SNPs
and haplotypes with ONFH.
Results: The 4G allele of rs1799889, A allele of rs2227631, and C allele of rs11178 were significantly associated with
increased ONFH risk (p = 0.03, p = 0.003, and p = 0.002, respectively). When we divided the population according
to gender, an association between the three SNPs and increased risk of ONFH was found only in men. In another
subgroup analysis based on the etiology of ONFH, rs2227631 (A allele) and rs11178 (C allele) in the idiopathic
subgroup (p = 0.007 and p = 0.021) and rs1799889 (4G allele) and rs11178 (C allele) in the alcohol-induced
subgroup (p = 0.042 and p = 0.015) were associated with increased risk of ONFH. In addition, a certain haplotype
(A-4G-C) of PAI-1 was also significantly associated with ONFH (p < 0.001).
Conclusion: Our findings demonstrated that three SNPs (rs1799889, rs2227631, and rs11178) of the PAI-1 gene
were associated with ONFH risk. This study also suggests that PAI-1 SNPs may play an important role in ONFH.
Background
Osteonecrosis of the femoral head (ONFH) is a devas-
tating bone disease in which patients experience pro-
gressive collapse of the femoral head caused by a
disturbance in the supply of blood and anomalies in the
fibrinolytic system [1,2]. An increased tendency for
intravascular coagulation is proposed as the pathoge-
netic mechanism responsible for interruption of the oss-
eous blood supply and ONFH, and a significantly higher
prevalence of coagulation abnormalities is reported in
patients with ONFH [1,3]. Recent studies have suggested
that genetic polymorphisms in factor V, prothrombin,
methylenetetrahydrofolate reductase (MTHFR), and
plasminogen activator inhibitor-1 (PAI-1) genes leading
to intravascular coagulation disorders may be related to
ONFH [4-6].
PAI-1 is a critical factor that regulates coagulation and
fibrinolytic systems. Reduced plasma fibrinolytic activity,
mainly attributable to increased levels of PAI-1, is asso-
ciated with ONFH development [7,8]. Previously, PAI-1
levels were reported to be regulated by a common tran-
scription-altering insertion/deletion single nucleotide poly-
morphism (SNP; rs1799889) of four or five guanine (4G/
5G) nucleotides that is 675 bp upstream of the transcrip-
tion start site. Homozygous or heterozygous carriage of
the 4G allele is associated with higher PAI-1 levels [9]. In
myocardiac infarction, subjects who are homozygous for
t h e4 Ga l l e l e( 4 G / 4 Gg e n o t ype) have plasma PAI-1
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those of subjects who are homozygous for the 5G allele
(5G/5G genotype) [10]. Glueck et al. first reported that the
genotype frequency of 4G/4G was 41% in ONFH patients
and 20% in healthy control subjects [8]. Moreover, Ferrari
et al. reported a significant increase in the frequency of the
4G/4G genotype in renal transplant patients with ONFH
compared to that of controls (60.3% vs. 20.6%) [7]. How-
ever, Asano et al. suggested that plasma PAI-1 levels are
highest in ONFH patients with the 4G/4G genotype, but
that the incidence of ONFH is not related to genotype
[11]. To better understand the genetic influences of PAI-1
on ONFH, we selected SNPs in the promoter and 3’UTR
that are known to be involved in the regulation of gene
expression. To determine whether PAI-1 SNPs, including
4G/5G, are associated with susceptibility to ONFH, geno-
type and allele frequencies were analyzed. We also investi-
gated whether pathological etiology (idiopathic, alcohol-




A total of 206 (159 men, 47 women; mean age 44.2 ±
11.6) patients with non-traumatic ONFH who had total
hip arthroplasty at Kyunghee University Hospital (Seoul,
Korea) were consecutively enrolled in this study. The
diagnosis of symptomatic ONFH was based on antero-
posterior and lateral pelvic radiography and magnetic
resonance images. Patients were subgrouped according
to etiological factors into idiopathic (98 cases), steroid-
induced (72 cases), and alcohol-induced (36 cases)
ONFH. Patients with a demonstrable history of direct
trauma or with possible combined causes were excluded.
Steroid-induced ONFH was defined by a history of tak-
ing prednisolone 1800 mg or the equivalent over 4
weeks with nephritic syndrome, and organ transplanta-
tion [12]; and alcohol-induced ONFH was diagnosed
based on the consumption of more than 400 ml of alco-
hol per week [13]. Patient characteristics are summar-
ized in Table 1.
Controls were recruited from subjects attending rou-
tine medical checkups at our institution who had no
coagulation-related disorder or other chronic disease,
such as diabetes or cardiovascular disease (CHD). Con-
trol subjects were matched with patients with regard to
gender and age (193 men, 58 women; mean age 47.8 ±
12.6). This study was approved by the Institutional
Review Board at our hospital, and informed consent was
obtained from all patients.
Polymerase chain reaction and genotyping
Genomic DNA was isolated from peripheral blood leu-
kocytes using an AxyPrep Blood Genomic DNA Mini-
prep kit (Axygen Biosciences, Union, CA, USA). The
~1.0 kb promoter region of the PAI-1 gene was partially
amplified using PCR and analyzed via direct sequencing.
All PCR reactions were in a 20 μl volume containing 1.5
mmol/L MgCl2,4 0m m o l / LK C l ,1 0m m o l / LT r i s - H C l
(pH 9.0), 250 μmol/L dNTP, 1 U Taq DNA polymerase
(Bioneer, Daejeon, Korea) and 50 ng genomic DNA in
distilled water. The forward primer 5’ GTG CTT GAA
T C AT C CC G AA A C3 ’ and reverse primer 5’ TCT
GGA CCA CCT CCA GGA AA 3’ were used for ampli-
fication. The conditions for the PCR reaction were
denaturation at 95°C for 10 min, followed by 35 cycles
of denaturation at 95°C for 30 sec, annealing at 58°C for
30 sec, and extension at 72°C for 30 sec, followed by a
final extension at 72°C for 10 min. PCR products puri-
fied with 95% ethyl alcohol were used as template DNA
for cycle sequencing. The PCR for sequencing was per-
formed using a Big Dye Terminator (ver 3.1) cycle
sequencer and analyzed using an ABI Prism
® 3730
Automated DNA sequencer (Applied Biosystems, Foster
City, CA, USA).
T h eS N Po ft h eP A I - 13 ’UTR (rs11178) was analyzed
with primers and probes for TaqMan
® SNP genotyping
assays. Primer Express (Applied Biosystems, Foster City,
CA, USA) was used to design both the PCR primers
and the MGB TaqMan
® probes. One allelic probe was
labeled with 6-carboxyl-fluorescent (FAM)™ dye and
the other was labeled with fluorescent VIC
® dye. PCRs
were carried out in TaqMan
® Universal Master mix
without UNG (Uracil-N-Glycosylase; Applied Biosys-
tems), containing PCR primer concentrations of 900 nM
and TaqMan
® MGB-probe concentrations of 200 nM.
Reactions occurred in a 96-well plate with a total reac-
tion volumes of 10 μl using 20 ng of genomic DNA.
Table 1 Characteristics of ONFH patients and controls
Controls Patients









a 47.8 ± 12.6 44.2 ± 11.6 44.9 ± 12.3 45.7 ± 10.2 39.3 ± 10.9
Sex (M/F) 193/58 159/47 78/20 62/10 19/17
BMI (kg/m
2)
a 23.6 ± 3.5 24.2 ± 3.3 24.4 ± 3.6 24.1 ± 2.9 24.4 ± 3.3
aMean ± SEM
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Applied Biosystems, Foster City, CA, USA) and heated
at 50°C for 2 min and 95°C for 10 min, followed by 40
cycles at 92°C for 15 sec and 60°C for 1 min, with post-
reading at 60°C for 1 min. Fluorescence data files were
analyzed using automated allele-calling software (SDS
2.1, Applied Biosystems, Foster City, CA, USA). Geno-
typing quality control was performed in 10% of samples
via duplicate checking (rate of concordance in duplicates
> 99%).
Statistical analysis
We tested significant deviations in genotype frequency
from Hardy-Weinberg equilibrium (HWE) at each poly-
morphic variant using the c
2 t e s t .O d d sr a t i o s( O R s )
and 95% confidence intervals (CIs) were used to esti-
mate the relative risks of ONFH patients associated with
the presence of different PAI-1 genotypes. We employed
aw i d e l yu s e dm e a s u r eo fl i n k a g ed i s e q u i l i b r i u m( L D )
between all pairs of biallelic loci, D’,a n dr
2.H a p l o t y p e
structures and their frequencies were estimated from
genotyped data using Haploview http://www.broad.mit.
edu/mpg/haploview based on the expectation maximiza-
tion (EM) algorithm. The c
2 test was used to compare
the frequencies of discrete variables between ONFH
patients and controls. All statistical analyses were per-
formed using SPSS for Windows version 16.0 and p-
values less than 0.05 were regarded as significant. All
statistical tests were two-sided.
Results
To identify if PAI-1 SNPs were involved in susceptibility
to ONFH, three SNPs in the promoter and 3’UTR were
selected based on a minor allele frequency (MAF) >
0.05 and Hardy-Weinberg equilibrium (HWE) > 0.05
using a public database http://www.ncbi.nlm.nih.gov/
SNP/. Two SNPs (rs2227631, -844 G/A; rs1799889, -675
4G/5G) in the promoter region and one (rs11178,
+10700 C/T) in the 3’UTR of the PAI-1 gene were gen-
otyped in 206 ONFH and 251 control subjects (Table 2).
The p value of each polymorphism was determined for
comparison between ONFH patients and controls. The
rs2227631, rs1799889, and rs11178 genotypes and/or
allele frequencies of the PAI-1 gene were significantly
associated with ONFH risk (p = 0.002 - 0.03). These
results suggest that the minor alleles of rs2227631 (A),
rs1799889 (4G), and rs11178 (C) in the PAI-1 gene con-
tribute to an increase in ONFH risk (Table 3).
Further analysis based on pathological etiology (idio-
pathic, alcohol- or steroid-induced) showed that the
allele frequencies of PAI-1 (rs2227631 and rs11178)
between idiopathic ONFH patients and controls were
significantly associated (p = 0.007 and 0.021). In addi-
tion, the allele frequencies of rs1799889 and rs11178
were significantly associated with the alcohol-induced
ONFH subgroup (p = 0.042 and 0.015, respectively).
These results suggest that the PAI-1 SNPs were impor-
tant risk factors in idiopathic (rs2227631, rs11178) and
alcohol-induced (rs1799889, rs11178) ONFH (Table 4).
In addition, the association of PAI-1 polymorphisms
was further analyzed in the ONFH subgroup stratified
according to gender. Interestingly, the genotype frequen-
cies of rs2227631, rs1799889, and rs11178 were signifi-
cantly associated with ONFH in men but not in women
(Table 5). These results suggest that the PAI-1 SNPs
might be important genetic factors in ONFH suscept-
ibility in men.
We analyzed linkage LDs among the PAI-1 SNPs and
did not observe complete LD for the PAI-1 gene. LD
between SNPs was estimated by calculating the D’
values (Table 6). We also calculated the haplotype fre-
quencies of rs2227631, rs1799889, and rs11178 in
ONFH patients and controls. The distribution of haplo-
type A-4G-C was significantly different between the
ONFH patients and controls (p < 0.001) (Table 7).
These results suggest that these SNPs should be further
analyzed in future studies regarding PAI-1 functions and
ONFH.
Discussion
We determined the contributions of PAI-1 gene SNPs
to ONFH. We identified for the first time a significant
association between SNPs of the PAI-1 gene (rs2227631;
-844 G/A, rs1799889; -675 4G/5G, rs11178; +10700 C/
T) and ONFH in Koreans. The A, 4G, and C alleles
considerably increased disease risk (Table 3).
Table 2 Frequencies of PAI-1 polymorphisms (n = 457)
Position
a Location Genotype MAF
c Heterozygosity
g.-844G/A promoter GG GA AA N 0.387 0.425
(rs2227631) 183 194 80 457
g.-6754G/5G promoter 4G4G 4G5G 5G5G N 0.410 0.492
(rs1799889) 157 225 75 457
g.10700 3’-UTR
b CC CT TT N 0.500 0.457
(rs11178) 124 209 124 457
ars No. was shown if present in the dbSNP database;
b3’-untranslated region;
cfrequencies of minor alleles
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Page 3 of 7PAI-1 is a fast-acting inhibitor of fibrinolysis, and
increased plasma levels are associated with increased
incidence of thrombophilia [14] and osteonecrosis
[8,11,15,16]. High levels of PAI-1, induced by -675 4G/
5G SNP in the PAI-1 promoter, lead to suppression of
fibrinolysis through inhibition of plasminogen activator
and promotion of thrombosis. The resulting increase in
intraosseous venous pressure which restricts flow to the
femoral head may culminate in osteonecrosis [8,16]. The
PAI-1 gene is reported to be polymorphic, especially in
rs1799889 (-675 4G/5G) of the promoter region. The
possible association between rs1799889 and osteonecro-
sis risk has been studied, leading to controversial results.
Glueck et al. and Ferrari et al. reported that the 4G
allele is a major predisposing factor in ONFH patients
[7,8], but the findings of Asano et al. were contradictory
to that conclusion [11]. Glueck et al. showed that, in
Americans, twice as many patients as healthy control
subjects (41% vs. 20%) were homozygous for 4G/4G,
and 19% of patients and 36% of the control subjects had
the 5G/5G genotype (p = 0.001) [7]. Furthermore, Fer-
rari P. et al. observed that in 228 glucocorticoid-treated
renal transplant patient in Switzerland, the prevalence of
ONFH according to genotype was 1.8% for 5G/5G, 7.7%
for 4G/5G, and 30.3% for 4G/4G (p < 0.001 vs. 4G/5G
and 5G/5G); the prevalence of ONFH according to gen-
otype in subjects with persistent hyperparathyroidism
was 4.2% for 5G/5G, 15.2% for 4G/5G, and 55.5% for
Table 3 Genotypes and allelic frequencies of PAI-1 gene polymorphisms between ONFH patients (n = 206) and
controls (n = 251)
Position Genotype/Allele Controls, n (%) Patients, n (%) OR (95% CI) p
g.-844G/A GG 116(46.2) 67(32.5) 1* 0.011
(rs2227631) GA 97(38.6) 97(47.1) 1.73(1.15-2.61)
AA 38(15.1) 42(20.4) 1.91(1.12-3.26)
G 329(65.5) 231(56.1) 1* 0.003
A 173(34.5) 181(43.9) 1.49(1.14-1.95)
g.-6754G/5G 5G5G 46(18.3) 29(14.1) 1* 0.073
(rs1799889) 4G5G 130(51.8) 95(46.1) 1.16(0.68-1.98)
4G4G 75(29.9) 82(39.8) 1.73(0.99-3.04)
5G 222(44.2) 153(37.1) 1* 0.030
4G 280(55.8) 259(62.9) 1.34(1.03-1.75)
g.10700C/T TT 79(31.5) 45(21.8) 1* 0.013
(rs11178) CT 116(46.2) 93(45.1) 1.41(0.89-2.22)
CC 56(22.3) 68(33.0) 2.13(1.28-3.55)
T 274(54.6) 183(44.4) 1* 0.002
C 228(45.4) 229(55.6) 1.50(1.16-1.95)
*reference category (odds ratio, 1.0)
Table 4 Genotypes and allelic frequencies of PAI-1 gene polymorphisms between ONFH subtype patients (n = 206)
and controls (n = 251)
Patients p
Position Genotype Controls Idi
a Alc
b Ste
c vs Idi Alc Ste
g.-844G/A G 329(65.5) 107(54.6) 83(57.6) 41(56.9) 0.007 0.082 0.154
(rs2227631) A 173(34.5) 89(45.4) 61(42.4) 31(43.1)
GG+GA 213(84.9) 75(76.5) 61(84.7) 28(77.8) 0.066 0.977 0.279
AA 38(15.1) 23(23.5) 11(15.3) 8(22.2)
g.-6754G/5G 5G 222(44.2) 76(38.8) 50(34.7) 27(37.5) 0.191 0.042 0.282
(rs1799889) 4G 280(55.8) 120(61.2) 94(65.3) 45(62.5)
4G5G+5G5G 176(70.1) 61(62.2) 41(56.9) 22(61.1) 0.157 0.036 0.274
4G4G 75(29.9) 37(37.8) 31(43.1) 14(38.9)
g.10700C/T T 274(54.6) 88(44.9) 62(43.1) 33(45.8) 0.021 0.015 0.164
(rs11178) C 228(45.4) 108(55.1) 82(56.9) 39(54.2)
TT+CT 195(77.7) 66(67.3) 47(65.3) 25(69.4) 0.046 0.032 0.274




Kim et al. BMC Musculoskeletal Disorders 2011, 12:160
http://www.biomedcentral.com/1471-2474/12/160
Page 4 of 74G/4G (p < 0.003 vs. 4G/5G and p < 0.001 vs. 5G/5G)
[8]. Asano et al. studied 31 Japanese patients with post-
renal transplant ONFH and found four patients with
5G/5G, 11 with 4G/5G, and 16 with 4G/4G. However,
analysis revealed no significant differences in the inci-
dence of ONFH among these patients (p = 0.49) [11].
In addition to rs1799889, another SNP in the promo-
ter region of PAI-gene, rs2227631 (-844 G/A), is poten-
tially implicated in PAI-1 gene regulation. To date, a
significant association has been reported between this
SNP and coronary heart disease (CHD) in nonsmokers,
with patients having a higher frequency of rs2227631 A
allele. In addition to rs2227631 and rs1799889, rs11178
(+10700 C/T) also significantly associates with increased
CHD risk in nonsmokers. The correlation between
rs11178 and CHD in nonsmokers might be attributable
to strong linkage LD of this SNP with rs2227631 and
rs1799889 [17]. For ONFH, the results of our study con-
firmed an association between rs1799889 and disease
risk in a Korean population. Moreover, for the first
time, we showed that rs2227631 and rs11178 are essen-
tial SNPs involved in the regulation of PAI-1 gene
expression in ONFH (Table 3).
Several transcription factor binding sites for PAI-1 are
found in the 5’ and 3’ UTR regions, and the transcrip-
tional regulation of the gene is extremely complex [18].
Several studies have shown that SNPs within the 5’UTR
lead to differences in PAI-1 expression between indivi-
duals, and this could influence the etiology of a variety
of pathological conditions with which PAI-1 is asso-
ciated such as cancer, rheumatoid arthritis and stroke
[19-21]. We classified ONFH into two or three major
subgroups based on etiology and gender: idiopathic,
alcohol-induced, steroid-induced groups, and men and
women. We found that the risk effects of rs2227631 and
rs11178 in the idiopathic subgroup, rs1799889 and
rs11178 in the alcohol-induced subgroup, and all three
SNPs in men were significantly associated with ONFH.
However, no association was seen in the steroid-induced
group or in women. Glucocorticoid has been reported
to increase PAI-1 activity and is a potential risk factor
for ONFH development [7,22]. However, we had limited
data on SNPs of PAI-1 in steroid-induced ONFH. The
incidence of ONFH is relatively low and gender-biased.
We examined 206 cases, of which 159 (77%) were men.
Moreover, epidemiologic analysis showed that the inci-
dence of steroid-induced ONFH in overall ONFH was
low (17.5%). In Korean studies, the proportion of ster-
oid-induced ONFH was previously shown to be small
(range, 12.6% to 15.4%) [23,24]. We found that, in Kor-
eans, steroid-induced ONFH is more rare than idio-
pathic or alcohol-induced ONFH. Thus, we found no
significant association between PAI-1 SNPs and steroid-
induced ONFH because of the small sample size. In
addition, differences according to subgroup could not be
clearly distinguished. Therefore, the association analysis
strategy of subgrouping according to gender or etiology
has limitations. However, the results of the steroid-
induced group showed a similar tendency as those of
the other groups, demonstrating that patients more
often have risk alleles (A, 4G, and C) than do control
subjects, although this finding was not significant (Table
4 and 5). Thus, we suggest that PAI-1 SNPs are involved
in ONFH risk in Korean patients. To firmly establish the
relationship between the PAI-1 SNPs and steroid-
induced ONFH, further study with larger sample sizes is
required.
The pathophysiology of ONFH is not well known,
although a number of polymorphisms in candidate
genes (HIF-1, VEGF, eNOS, IL23R, SREBP-2, ANXA6)
were recently identified in an attempt to determine the
Table 5 Genotype frequencies of PAI-1 gene polymorphisms between ONFH patients and controls in men and women
Men Women
Position Genotype Controls Patients p Controls Patients p
g.-844G/A GG 92(47.7) 53(33.3) 0.025 24(41.4) 14(29.8) 0.386
(rs2227631) GA 71(36.8) 74(46.5) 26(44.8) 23(48.9)
AA 30(15.5) 32(20.1) 8(13.8) 10(21.3)
g.-6754G/5G 5G5G 37(19.2) 21(13.2) 0.030 9(15.5) 8(17.0) 0.976
(rs1799889) 4G5G 102(52.8) 73(45.9) 28(48.8) 22(46.8)
4G4G 54(28.0) 65(40.9) 21(36.2) 17(36.2)
g.10700C/T TT 62(32.1) 33(20.8) 0.003 17(29.3) 12(25.5) 0.718
(rs11178) CT 91(47.2) 69(43.4) 25(43.1) 24(51.1)
CC 40(20.7) 57(35.8) 16(27.6) 11(23.4)
Table 6 LD coefficients (|D’ |) and r
2 among
polymorphisms in the PAI-1 gene
|D’|
SNPs rs2227631 rs1799889 rs11178
r
2 rs2227631 - 0.932 0.786
rs1799889 0.382 - 0.786
rs11178 0.391 0.43 -
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Korean population [24-29]. Some studies have suggested
that genetic polymorphisms leading to thrombosis (fac-
tor V, prothrombin, MTHFR) may be related to ONFH
[4,6,16,30,31]. Intravascular coagulopathy including
thrombotic and fibrinolytic abnormalities may play an
etiologic role in the disease, and studies have investi-
gated the association between ONFH and genes
involved in the coagulation and fibrinolytic system
[7,11,32].
Conclusion
We found that SNPs of the PAI-1 gene, which is
involved in coagulation, were significantly correlated
with ONFH. These data suggest that PAI-1, along with
already reported candidate genes, may be useful genetic
markers to identify high-risk individuals in Korea. The
results of this association study suggest that PAI-1 gene
polymorphisms may be important genetic factors in
ONFH susceptibility in a Korean population. To further
substantiate this hypothesis, functional studies of PAI-1
regulation are required. The polymorphisms analyzed in
this study may contribute to further studies on the func-
tion of PAI-1 and the development of ONFH.
Abbreviations
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